(HealthDay News) — Younger patients have a higher risk for financial toxicity following robotic prostate cancer surgery, according to a study published in The Journal of Urology.
Oktay Özman, MD, from the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital in Amsterdam, and colleagues evaluated the frequency of financial toxicity among patients who underwent robot-assisted radical prostatectomy for prostate cancer. The analysis included 1479 robot-assisted radical prostatectomy patients between 2006 and 2021 reporting no financial toxicity in preoperative assessments.
The researchers found that through 2 years of follow-up, 8.3% reported financial toxicity. There were no statistically significant differences between financial toxicity and salvage radiotherapy and positive surgical margin rates. Age at robot-assisted radical prostatectomy (odds ratio [OR], 0.95), International Prostate Symptom Score (OR, 2.4), International Consultation on Incontinence Questionnaire-Short Form (OR, 1.5), and quality-of-life scores (OR, 0.09) were associated with financial toxicity. There was a 1.6-fold increased financial toxicity risk among patients who underwent robot-assisted radical prostatectomy before retirement (65 years of age or younger).
“Patients who report urological symptoms after robot-assisted radical prostatectomy should also be evaluated for financial toxicity,” the authors write.
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
– Clinical News, with personalized daily picks for you
– Case Studies
– Conference Coverage
– Full-Length Features
– Drug Monographs
– And More
Want to read more?
Please login or register first to view this content.